ATSN-101

N/A

Report date: 2024/01/18 09:32:27

Base Information

Drug NameATSN-101
Drug Alias NameAdeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)SAR-439483ATSN-101
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionRetinal guanylyl cyclase 1 gene transference
TargetsRetinal guanylyl cyclase 1
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida
China Registration ClassN/A

Develop Information

Active CompaniesSanofiAtsena TherapeuticsNippon Shinyaku Co Ltd
Inactive CompaniesN/A
Active IndicationsLeber Congenital Amaurosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A